To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.

Primary Objectives

-To determine the incidence of protocol specified pre-surgery MRD-positivity in IBC (assessment between completion of planned systemic therapy and surgery).

Secondary Objectives

• To establish the feasibility of multi-institutional MRD data collection using standard of care Signatera analysis in IBC participants.
• To evaluate the association of pre-surgery MRD to pathologic response.
• To evaluate participant reported QOL for worry about recurrence based in participants receiving MRD results
• To establish protocol-optional baseline and longitudinal MRD data collection in IBC participants and report the frequency of MRD longitudinally
• To determine the median lead time between the first MRD-positive result and clinical recurrence.
• To determine whether adjuvant therapies decrease the amount of MRD in participants, and the association with relapse.

Inclusion Criteria:

• Female or males ≥18 years of age with the ability to understand and sign a written
• Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
• Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
• Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
• Participants must be English-speaking.

Exclusion Criteria:

-

MD Anderson Cancer Center